Sagimet Biosciences Inc. announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Dr. Grauer brings more than two decades of global biopharmaceutical leadership experience, with deep expertise spanning clinical development, medical affairs, and regulatory strategy across multiple therapeutic areas. He most recently served as Chief Medical Officer at Omeros Corporation, where he led all clinical, safety, and medical functions advancing a pipeline of complement-targeted therapies in hematologic and immune-mediated diseases.
Prior to Omeros, Dr. Grauer held Chief Medical Officer roles at Federation Bio and Corcept Therapeutics Incorporated, where he built and led global development organizations, advanced first-in-class programs into the clinic, and drove regulatory interactions across the U.S., Europe, and other major markets. Earlier in his career, Dr. Grauer spent over a decade at Amgen Inc. in senior global development leadership roles, including Therapeutic Area Head for Bone, Nephrology, and Inflammation, with responsibility for late-stage programs, global filings, and lifecycle strategy for multiple blockbuster assets. He began his industry career at Procter & Gamble Pharmaceuticals in medical affairs.
In addition to his industry experience, Dr. Grauer is a physician-scientist with over 120 peer-reviewed publications, including in leading journals such as The New England Journal of Medicine and The Lancet, and continues to serve as an Associate Professor of Medicine at the University of Heidelberg Medical School, Germany, where he received his MD and also completed his clinical training in internal medicine and endocrinology. Sagimet?s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, has retired effective April 20, 2026 and will continue to support the Company as an external scientific advisor.
